<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00198562</url>
  </required_header>
  <id_info>
    <org_study_id>H16-CV-001</org_study_id>
    <secondary_id>200400510B</secondary_id>
    <nct_id>NCT00198562</nct_id>
  </id_info>
  <brief_title>Hypertension Control Based on Home Blood Pressure</brief_title>
  <official_title>Hypertension Control Based on Home Systolic Pressure Study (HOSP Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Japan Cardiovascular Research Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Ministry of Health, Labour and Welfare, Japan</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this trial is to study the effects of antihypertensive therapy based on home
      systolic blood pressure (BP) with different target levels using two classes of drugs.

      The HOSP study is a multicenter, prospective, randomized, open, blinded endpoint study. The
      study subjects are 40-79 years old hypertensive patients. After a 4 weeks of baseline period,
      subjects are randomly assigned to (1) modest control group (morning home BP &lt;140 mmHg) or (2)
      strict control group (morning home BP &lt;130 mmHg), and to (a) amlodipine group or (b) losartan
      group. Additional antihypertensive drugs can be used if home BP is not controlled. Home BP is
      measured in the early morning and late evening. The participants will be followed up for 5
      years.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of this trial is to study the effects of antihypertensive therapy based on home
      systolic blood pressure (BP) with different target levels using two classes of drugs.

      The HOSP study is a multicenter, prospective, randomized, open, blinded endpoint study.
      Inclusion criteria are 40-79 years old treated or untreated hypertensive patients without
      serious medical conditions. After a 4 weeks of baseline period, subjects are randomly
      assigned to (1) modest control group (target morning home BP &lt;140 mmHg) or (2) strict control
      group (morning home BP &lt;130 mmHg), and to (a) amlodipine group (2.5-5 mg od) or (b) losartan
      group (25-50 mg od). Additional antihypertensive drugs (diuretics, beta-blockers and
      alpha-blockers) can be used if home BP is not controlled. Home BP is measured in the early
      morning and late evening. Primary end point is combined cardiovascular events.The
      participants will be followed up for 5 years.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2000</start_date>
  <completion_date type="Anticipated">March 2012</completion_date>
  <primary_completion_date type="Anticipated">March 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Combined cardiovascular events</measure>
    <time_frame>5 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total mortality</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular mortality</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction and new-onset angina</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke and transient ischemic attack</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal failure</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aortic and peripheral artery diseases</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular mass and function</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary albumin and renal function</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2600</enrollment>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>target morning home blood pressure (below 130 mmHg vs 130-139 mmHg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>antihypertensive drug (amlodipine vs losartan)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine, Losartan</intervention_name>
    <description>amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>other antihypertensive drugs (if required)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of hypertension

        Exclusion Criteria:

          -  Severe hypertension (treated with 3 or more antihypertensive drugs)

          -  Unable to change antihypertensive drugs to a calcium antagonist or an angiotensin
             antagonist

          -  Serious medical conditions

          -  Women who may become to be pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yuhei Kawano, M.D., Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Hypertension and Nephrology, National Cardiovascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>April 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2005</study_first_posted>
  <last_update_submitted>April 18, 2008</last_update_submitted>
  <last_update_submitted_qc>April 18, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 22, 2008</last_update_posted>
  <responsible_party>
    <name_title>Yuhei Kawano, M.D., Ph.D., Director of Division of Hypertension and Nephrology</name_title>
    <organization>National Cardiovascular Center</organization>
  </responsible_party>
  <keyword>Antihypertensive therapy</keyword>
  <keyword>Home blood pressure</keyword>
  <keyword>Systolic blood pressure</keyword>
  <keyword>Morning blood pressure</keyword>
  <keyword>Calcium antagonist</keyword>
  <keyword>Angiotensin receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
    <mesh_term>Losartan</mesh_term>
    <mesh_term>Antihypertensive Agents</mesh_term>
    <mesh_term>Angiotensin Receptor Antagonists</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

